SAN CARLOS, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will participate in the following event in September:
Bank of America 37th Annual Investment Conference September 17, 2007 3:30pm, PT Dr. Ted W. Love, Chairman and CEO Presentation: http://www.veracast.com/webcasts/bas/37th-annual-2007/id42116402.cfm Breakout: http://www.veracast.com/webcasts/bas/37th-annual-2007/id89117822.cfm
A live audio webcast of the presentation will also be available online via the Investor Relations portion of Nuvelo's website at http://www.nuvelo.com.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic-related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.CONTACT: Nicole Foderaro of WeissComm Partners, Inc., +1-415-946-1058,nfoderaro@weisscommpartners.com
Web site: http://www.nuvelo.com/
